Past, present and future drugs for the treatment of obsessive-compulsive disorder

Current Medicinal Chemistry

Volumn 17, Issue 29, 2010, Pages 3410-3421

  Marazziti, D ^a   Consoli, G ^a   Baroni, S ^a   Dell'Osso, M Catena ^a  

^a UNIVERSITY OF PISA   (Italy)

Author keywords

Anti obsessive new compounds; Antidepressants; Clomipramine; Obsessive compulsive disorder; Pharmacological treatment; Resistance; Selective serotonin reuptake inhibitors

Indexed keywords

ANTIDEPRESSANT AGENT; CITALOPRAM; CLOMIPRAMINE; CYCLOSERINE; DULOXETINE; ESCITALOPRAM; FLUOXETINE; FLUVOXAMINE; GLUTAMIC ACID; INOSITOL; MORPHINE; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NEUROPEPTIDE; NEUROTRANSMITTER; PAROXETINE; PIMOZIDE; QUETIAPINE; RILUZOLE; RISPERIDONE; SEROTONIN; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; VENLAFAXINE;

ARTICLE; CLINICAL PRACTICE; HUMAN; NEUROTRANSMISSION; OBSESSIVE COMPULSIVE DISORDER; PATHOPHYSIOLOGY; SECOND MESSENGER; TREATMENT OUTCOME; TREATMENT RESPONSE;

EID: 77957969756     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986710793176384     Document Type: Article

References (175)

1. American Psychiatric Association Comitee on Nomenclature and Statistics. Diagnostic and Statistical Manual of Mental Disorders, Ed. 4. American Psychiatric Press: Washington, DC, 1994.
2. Karno, M.; Golding, J. M.; Sorenson, S. B.; Burnam, M. A. The epidemiology of obsessive-compulsive disorder in five US communities. Arch. Gen. Psychiatry, 1988, 45, 1094-1099.
3. Kessler, R. C.; McGonagle, K. A.; Zhao, S.; Nelson, C. B.; Hughes, M.; Eshleman, S.; Wittchen, H. U.; Kendler, K. S. Lifetime and 12-month prevalence of DSM-III-R psychiatric disorders in the United States. Results from the National Comorbidity Survey. Arch. Gen. Psychiatry, 1994, 51, 8-19.
4. Hollander, E.; Stein, D. Obsessive-compulsive disorder. Oxford Press: 1999.
5. th ed. In: Kaplan HI, Sadock BJ, Ed. Lippincott Williams & Wilkins, 2004; pp. 1104-1126.
6. Weissman, M. M.; Bland, R. C.; Canino, G. J.; Greenwald, S.; Hwu, H. G.; Lee, C. K.; Newman, S. C.; Oakley-Browne, M. A.; Rubio-Stipec, M.; Wickramaratne, P. J.; Klerman, G.L.; Leon, A.C.; Warshaw, M.G. The cross national epidemiology of obsessive compulsive disorder. The Cross National Collaborative Group. J. Clin. Psychiatry, 1994, 55, 5-10.
7. Hollander, E.; Weilgus-Kornwasser, J. Counting the costthe psychosocial and economic burden of OCD. Focus on OCD. 1997, 5, 3-5.
8. Abramowitz, J. S.; Taylor, S.; McKay, D. Obsessive-compulsive disorder. Lancet, 2009, 374, 491-499.
9. Fullana, M. A.; Mataix-Cols, D.; Caspi, A.; Harrington, H.; Grisham, J. R.; Moffitt, T. E.; Poulton, R. Obsessions and compulsions in the community: prevalence, interference, help-seeking, developmental stability, and co-occurring psychiatric conditions. Am. J. Psychiatry, 2009, 166, 329-336.
10. Mayerovitch, J. I.; du Fort, G. G.; Kakuma, R.; Bland, R. C.; Newman, S. C.; Pinard, G. Treatment seeking for obsessivecompulsive disorder: role of obsessive-compulsive disorder symptoms and comorbid psychiatric diagnoses. Compr. Psychiatry, 2003, 44, 162-168.
11. Karno, M.; Golding, J. M. Obsessive compulsive disorder, in Psychiatric Disorders in America: The Epidemiological Catchment Area Study. In: Robins, L.; Reiger, D. A.; Ed. New York, Free Press, 1991; pp. 204-219.
12. Bland, R. C.; Orn, H.; Newman, S. C. Lifetime prevalence of psychiatric disorders in Edmonton. Acta Psychiatr. Scand. Suppl., 1988, 338, 24-32.
13. Kolada, J. L.; Bland, R. C.; Newman, S. C. Epidemiology of psychiatric disorders in Edmonton. Obsessive-compulsive disorder. Acta Psychiatr. Scand. Suppl., 1994, 376, 24-35.
14. Lopez-Ibor, J. J.; Fernandez-Cordobe, E. La clomipramina enfermos resistentes a otros tratamiantos. Acta Luso-Espan. Neurol. Psiquiatria, 1967, 26, 119-147.
15. Montgomery, S. A. Pharmacological treatment of obsessivecompulsive disorder. In: Hollander, E.; Zohar, J.; Marazziti, D.; Oliver, B.; Ed. Current insights in obsessive-compulsive disorder. Chichester, Wiley & Sons, 1994; pp. 215-226.
16. Greist, J. H.; Jefferson, J. V.; Kobak, K. A.; Katzelnick, D. J.; Serlin, R. C. Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch. Gen. Psychiatry, 1995, 52, 53-60.
17. Piccinelli, M.; Pini, S.; Bellantuono, C.; Wilkinson, G. Efficacy of drug treatment in obsessive-compulsive disorder. A meta-analytic review. Br. J. Psychiatry, 1995, 166, 424-443.
18. Finiberg, N. Refining treatment approaches in obsessivecompulsive disorder. Int. Clin. Psychopharmacol., 1996, 11, 13-22.
19. Hoehn-Saric, R.; Ninan, P.; Black, D. W.; Stahl, S.; Greist, J. H.; Lydiard, B.; McElroy, S.; Zajecka, J.; Chapman, D.; Clary, C.; Harrison, W. Multicenter double blind comparison of sertraline and desipramine for concurrent obsessive-compulsive and major depressive disorders. Arch. Gen. Psychiatry, 2000, 57, 76-82.
20. Zohar, J.; Chopra, M.; Sasson, Y.; Amiaz, R.; Amital, D. Obsessive compulsive disorder: serotonin and beyond. World J. Biol. Psychiatry, 2000, 1, 92-100.
21. Skoog, G.; Skoog, J. A 40-year follow-up of patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1999, 56, 131-132.
22. Marks, I. M.; Hodgson, R.; Rachman, S. Treatment of chronic obsessive-compulsive neurosis by in vivo exposure. Br. J. Psychiatry, 1975, 127, 349-364.
23. Foa, E. B.; Steketee, G.; Milby, J. B. Differential effects of exposure and response prevention in obsessive-compulsive washers. J. Consult. Clin. Psychol., 1980, 48, 71-79.
24. Foa, E. B.; Steketee, G.; Grayson, J. B.; Latimer, P. R. Deliberate exposure and blocking of obsessive-compulsive rituals: immediate and long-term effects. Behav. Ther., 1984, 15, 450-472.
25. Castle, D. J.; Deale, A.; Marks, I. M.; Cutts, F.; Chadhoury, Y.; Stewart, A. Obsessive-compulsive disorder: prediction of outcome from behavioral psychotherapy. Acta Psychiatr. Scand., 1994, 89, 393-398.
26. Perse, T. Obsessive-compulsive disorder: a treatment review. J. Clin. Psychiatry, 1988, 49, 48-55.
27. Steketee, G.; Cleere, L. Obsessional-compulsive disorder. In: Bellak, A. S.; Hersen, M.; Kazdin, E. A.; International handbook of behavior modification and therapy. Plenum Press, New York, 1990; pp. 307-332.
28. Abramowitz, J. S. Effectiveness of psychological and pharmacological treatments for obsessive-compulsive disorder: a quantitative review. J. Consult. Clin. Psychol., 1997, 65, 44-52.
29. Kobak, K. A.; Greist, J. H.; Jefferson, J. W.; Katzelnick, D. J.; Henk, H. J. Behavioral versus pharmacological treatments of obsessive compulsive disorder: a meta-analysis. Psychopharmacology, 1998, 136, 205-216.
30. Emmelkamp, P. M. G.; Visser, S.; Hoekstra, R. J. Cognitive therapy vs exposure in vivo in the treatment of obsessive compulsive disorder. Cogn. Ther. Res., 1988, 12, 103-114.
31. McLean, P. D.; Whittal, M. L.; Thordarson, D. S.; Taylor, S.; Söchting, I.; Koch, W. J.; Paterson, R.; Anderson, K. W. Cognitive versus behavior therapy in the group treatment of obsessivecompulsive disorder. J. Consult. Clin. Psychol., 2001, 69, 205-214.
32. van Oppen, P.; de Haan, E.; van Balkom, A. J.; Spinhoven, P.; Hoogduin, K.; van Dyck, R. Cognitive therapy and exposure in vivo in the treatment of obsessive compulsive disorder. Behav. Res. Ther., 1995, 33, 379-390.
33. Foa, E. B.; Liebowitz, M. R.; Kozak, M. J.; Davies, S.; Campeas, R.; Franklin, M. E.; Huppert, J. D.; Kjernisted, K.; Rowan, V.; Schmidt, A. B.; Simpson, H. B.; Tu, X. Randomized, placebocontrolled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 2005, 162, 151-161.
34. van Oppen, P.; van Balkom, A. J.; de Haan, E.; van Dyck, R. Cognitive therapy and exposure in vivo alone and in combination with fluvoxamine in obsessive-compulsive disorder: a 5-year follow-up. J. Clin. Psychiatry, 2005, 66, 1415-1422.
35. Christensen, H.; Hadzi, P.; Andrews, G.; Mattick, R. Behavior therapy and tricyclic medication in the treatment of obsessivecompulsive disorder: a quantitative review. J. Consult. Clin. Psychol., 1987, 55, 701-711.
36. van Balkom, A. J. L. M.; van Oppen, P.; Wermeulen, A. W. A.; van Dick, R.; Nauta, M. C. E.; Vorst, H. C. M. Meta-analysis of the treatment of Obsessive-Compulsive Disorder: a comparison of antidepressant, behavior and cognitive therapy. Clin. Psychol. Rev., 1994, 14, 359-381.
37. The Clomipramine Collaborative Study Group. Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1991, 48, 730-738.
38. Lydiard, R. B.; Brawman-Mintzer, O.; Ballenger, J. C. Recent developments in the psychopharmacology of anxiety disorders. J. Consult. Clin. Psychol., 1996, 64, 660-668.
39. Prasko, J.; Paskova, B.; Zalesky, R.; Novák, T.; Kopecek, M.; Bares, M.; Horácek, J. The effect of repetitive transcranial magnetic stimulation (rTMS) on symptoms in obsessive compulsive disorder. A randomized, double blind, sham controlled study. Neuro Endocrinol. Lett., 2006, 27, 327-332.
40. Sachdev, P. S.; Loo, C. K.; Mitchell, P. B.; McFarquhar, T. F.; Malhi, G. S. Repetitive transcranial magnetic stimulation for the treatment of obsessive compulsive disorder: a double-blind controlled investigation. Psychol. Med., 2007, 37, 1645-1649.
41. Alonso, P.; Pujol, J.; Cardoner, N.; Benlloch, L.; Deus, J.; Menchón, J. M.; Capdevila, A.; Vallejo, J. Right prefrontal repetitive transcranial magnetic stimulation in bsessive-compulsive disorder: a double-blind, placebo-controlled study. Am. J. Psychiatry, 2001, 158, 1143-1145.
42. Anderson, D.; Ahmed, A. Treatment of patients with intractable obsessive-compulsive disorder with anterior capsular stimulation. Case report. J. Neurosurg., 2003, 98, 1104-1108.
43. Gabriels, L.; Cosyns, P.; Nuttin, B.; Demeulemeester, H.; Gybels, J. Deep brain stimulation for treatment-refractory obsessivecompulsive disorder: psychopathological and neuropsychological outcome in three cases. Acta Psychiatry Scand., 2003, 107, 275-282.
44. Nuttin, B. J.; Gabriels, L. A.; Cosyns, P. R.; Meyerson, B. A.; Andréewitch, S.; Sunaert, S. G.; Maes, A. F.; Dupont, P. J.; Gybels, J. M.; Gielen, F.; Demeulemeester, H. G. Long-term electrical capsular stimulation in patients with obsessive-compulsive disorder. Neurosurgery, 2003, 52, 1263-1274.
45. Aouizerate, B.; Cuny, E.; Martin-Guehl, C.; Guehl, D.; Amieva, H.; Benazzouz, A.; Fabrigoule, C.; Allard, M.; Rougier, A.; Bioulac, B.; Tignol, J.; Burbaud, P. Deep brain stimulation of the ventral caudate nucleus in the treatment of obsessive-compulsive disorder and major depression. Case report. J. Neurosurg., 2004, 101, 682-686.
46. Sturm, V.; Lenartz, D.; Koulousakis, A.; Treuer, H.; Herholz, K.; Klein, J. C.; Klosterkötter, J. The nucleus accumbens: a target for deep brain stimulation in obsessive-compulsiveand anxietydisorders. J. Chem. Neuroanat., 2003, 26, 293-299.
47. Oliver, B.; Gascon, J.; Aparicio, A.; Yats, E.; Rodriguez, R.; Maestro De León, J. L.; García-Bach, M.; Soler, P. A. Bilateral anterior capsulotomy for refractory obsessive-compulsive disorders. Stereotact. Funct. Neurosurg., 2003, 81, 90-95.
48. Dougherty, D. D.; Baer, L.; Cosgrove, G. R.; Cassem, E. H.; Price, B. H.; Nierenberg, A. A.; Jenike, M. A.; Rauch, S. L. Prospective long-term follow-up of 44 patients who received cingulotomy for treatment-refractory obsessive-compulsive disorder. Am. J. Psychiatry, 2002, 159, 269-275.
49. Kim, C. H.; Chang, J. W.; Koo, M. S.; Kim, J. W.; Suh, H. S.; Park, I. H.; Lee, H. S. Anterior cingulotomy for refractory obsessive-compulsive disorder. Acta Psychiatr. Scand., 2003, 107, 283-290.
50. Montoya, A.; Weiss, A. P.; Price, B. H.; Cassem, E. H.; Dougherty, D. D.; Nierenberg, A. A.; Rauch, S. L.; Cosgrove, G. R. Magnetic resonance imaging-guided stereotactic limbic leukotomy for treatment of intractable psychiatric disease. Neurosurgery, 2002, 50, 1043-1052.
51. Woerdeman, P. A.; Willems, P. W.; Noordmans, H. J.; Berkelbach van der Sprenkel, J. W.; van Rijen, P. C. Frameless stereotactic subcaudate tractotomy for intractable obsessive-compulsive disorder. Acta Neurochir. (Wien). 2006, 148, 633-637.
52. Yaryura-Tobias, J. A.; Stevens, K. P.; Perez-Rivera, R.; Boullosa, O. E.; Neziroglu, F. Negative outcome after neurosurgery for refractory obsessive-compulsive spectrum disorder. World J. Biol. Psychiatry, 2000, 1, 197-203.
53. Maletzky, B.; McFarland, B.; Burt, A. Refractory obsessive compulsive disorder and ECT. Convulsive Ther., 1994, 10, 34-42.
54. Lavin, M. R.; Halligan, P. ECT for obsessive-compulsive disorder and schizophrenia. Am. J. Psychiatry, 1996, 153, 1652-1653.
55. Thomas, S. G.; Kellner, C. H. Remission of major depression and obsessive-compulsive disorder after a single unilateral ECT. J. ECT, 2003, 19, 50-51.
56. Fux, M.; Levine, J.; Aviv, A.; Belmaker, R. H. Inositol treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 1996, 153, 1219-1221.
57. Storch, E. A.; Merlo, L. J.; Bengtson, M.; Murphy, T. K.; Lewis, M. H.; Yang, M. C.; Jacob, M. L.; Larson, M.; Hirsh, A.; Fernandez, M.; Geffken, G. R.; Goodman, W. K. D-cycloserine does not enhance exposure-response prevention therapy in obsessivecompulsive disorder. Int. Clin. Psychopharmacol., 2007, 22, 230-237.
58. Coric, V.; Taskiran, S.; Pittenger, C.; Wasylink, S.; Mathalon, D. H.; Valentine, G.; Saksa, J.; Wu, Y. T.; Gueorguieva, R.; Sanacora, G.; Malison, R. T.; Krystal, J. H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiatry, 2005, 58, 424-428.
59. Lougee, L.; Hirschtritt, M.; Swedo, S. E. An open-label trial of riluzole, a glutamate antagonist, in children with treatment-resistant obsessive-compulsive disorder. J. Child. Adolesc. Psychopharmacol., 2007, 17, 761-767.
60. Koran, L. M.; Aboujaoude, E.; Bullock, K. D.; Franz, B.; Gamel, N.; Elliott, M. Double-blind treatment with oral morphine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychiatry, 2005, 66, 353-359.
61. Flament, M. F.; Rapoport, J. L.; Berg, C. J.; Sceery, W.; Kilts, C.; Mellström, B.; Linnoila, M. Clomipramine treatment of childhood obsessive-compulsive disorder: a double blind controlled study. Arch. Gen. Psychiatry, 1985, 42, 977-983.
62. Mavissakalian, M.; Turner, S. M.; Michelson, L.; Jacob, R. Trycyclcic antidepressant in obsessive-compulsive disorder. Antiobsessional or antidepressant agents? Am. J. Psychiatry, 1985, 142, 301-306.
63. Murphy, D. L.; Siever, L. J.; Insel, T. R. Therapeutic response to trycyclic antidepressants and related drugs in non affective disorder patient population. Prog. Neuro-Psychopharmacol. Biol. Psychiatry, 1985, 9, 3-13.
64. Katz, R. J.; De Veaugh-Geiss, J.; Landau, P. Clomipramine in obsessive-compulsive disorder. Biol. Psychiatry, 1990, 28, 401-414.
65. Song, F.; Freemantle, N.; Sheldon, T. A.; House, A.; Watson, P.; Long, A.; Mason, J. Selective serotonin reuptake inhibitors: metaanalysis of efficacy and acceptability. BMJ, 1993, 306, 683-687.
66. Mitchell, J.; Greenberg, J.; Finch, K.; Kovach, J.; Kipp, L.; Shainline, M.; Jordan, N.; Anderson, C. Effectiveness and economic impact of antidepressant medication: a review. Am. J. Manag. Care, 1997, 3, 323-330.
67. Anderson, I. M. Selective serotonin reuptake inhibitors versus trycyclcic antidepressants: a meta-analysis of efficacy and tolerability. J. Affect. Disord., 2000, 58, 19-36.
68. Danish University Antidepressant Group (DUAG). Citalopram: clinical effect profile in comparison with clomipramine. A controlled multicenter study. Psychopharmacology, 1986, 90, 131-138.
69. Danish University Antidepressant Group (DUAG). Paroxetine: a selective serotonin reuptake inhibitor showing better tolerance, but weaker antidepressant effect than clomipramine in a controlled multicenter study. J. Affect. Disord., 1990, 18, 289-299.
70. Montgomery, S. A.; Mc Auley, R.; Montgomery, D. B.; Dawling, S.; Braithwaite, R. A. Plasma concentration of clomipramine and desmethylclomipramine and clinical response in depressed patients. Postgrad. Med. J., 1980, 56, 130-133.
71. Tollefson, G. D.; Rampey, A. H.; Pottvin, J. H.; Jenike, M. A.; Rush, A. J.; kominguez, R. A.; Koran, L. M.; Shear, M. K.; Goodman, W.; Genduso, L. A. A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1994, 51, 559-567.
72. Greist, J. H.; Jefferson, J. W.; Kobak, K. A.; Chouinard, G.; DuBoff, E.; Halaris, A.; Kim, S. W.; Koran, L.; Liebowtiz, M. R.; Lydiard, B.; et al. A 1 year double-blind placebo-controlled fixed dose study of sertraline in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 1995, 10, 57-65.
73. Montgomery, S. A.; Kasper, S.; Stein, D.; Bang Hedegaard, K.; Lemming, O. M. Citalopram 20 mg, 40 mg and 60 mg are all effective and well tolerated compared with placebo in obsessivecompulsive disorder. Int. Clin. Psychopharmacol., 2001, 16, 75-86.
74. Hollander, E.; Allen, A.; Steiner, M.; Wheadon, D. E.; Oakes, R.; Burnham, D. B. Acute and long-term treatment and prevention of relapse of obsessive-compulsive disorder with paroxetine. J. Clin. Psychiatry, 2003, 64, 1113-1121.
75. Ninan, P. T.; Koran, L. M.; Kiev, A.; Davidson, J. R.; Rasmussen, S. A.; Zajecka, J. M.; Robinson, D. G.; Crits-Christoph, P.; Mandel, F. S.; Austin, C. High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J. Clin. Psychiatry, 2006, 67, 15-22.
76. Rabinowitz, I.; Baruch, Y.; Barak, Y. High-dose escitalopram for the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 2008, 23, 49-53.
77. Montgomery, S. A.; McIntyre, A.; Osterheider, M.; Sarteschi, P.; Zitterl, W.; Zohar, J.; Birkett, M.; Wood, A. J. A double-blind, placebo-controlled study of fluoxetine in patients with DSM-III-R obsessive-compulsive disorder. The Lilly European OCD Study Group. Eur. Neuropsychopharmacol., 1993, 3, 143-152.
78. Zitterl, W.; Meszaros, K.; Hornik, K.; Twaroch, T.; Dossenbach, M.; Zitterl-Eglseer, K.; Zapotoczky, H. G. Efficacy of fluoxetine in Austrian patients with obsessive-compulsive disorder. Wien Clin. Wochenschr., 1999, 111, 439-442.
79. Romano, S.; Goodman, W.; Tamura, R.; Gonzales, J. Long-term treatment of obsessive-compulsive disorder after an acute response: a comparison of fluoxetine versus placebo. J. Clin. Psychopharmacol., 2001, 21, 46-52.
80. Goodman, W. K.; Price, L. H.; Rasmussen, S. A.; Delgado, P. L.; Heninger, G. R.; Charney, D. S. Efficacy of fluvoxamine in obsessive-compulsive disorder. A doubleblind comparison with placebo. Arch. Gen. Psychiatry, 1989, 46, 36-44.
81. Goodman, W. K.; Kozak, M. J.; Liebowitz, M.; White, K. L. Treatment of obsessive-compulsive disorder with fluvoxamine: a multicentre, double-blind, placebo-controlled trial. Int. Clin. Psychopharmacol., 1996, 11, 21-29.
82. Hohagen, F.; Winkelmann, G.; Rasche-Ruchle, H.; Hand, I.; König, A.; Münchau, N.; Hiss, H.; Geiger-Kabisch, C.; Käppler, C.; Schramm, P.; Rey, E.; Aldenhoff, J.; Berger, M. Combination of behaviour therapy with fluvoxamine in comparison with behaviour therapy and placebo. Results of a multicentre study. Br. J. Psychiatry Suppl., 1998, 35, 71-78.
83. Milanfranchi, A.; Ravagli, S.; Lensi, P.; Marazziti, D.; Cassano, G. B. A double-blind study of fluvoxamine and clomipramine in the treatment of obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 1997, 12, 131-136.
84. Mundo, E.; Rouillon, F.; Figuera, M. L.; Stigler, M. Fluvoxamine in obsessive-compulsive disorder: similar efficacy but superior tolerability in comparison with clomipramine. Hum. Psychopharmacol., 2001, 16, 461-468.
85. Cottraux, J.; Mollard, E.; Bouvard, M.; Marks, I. Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year followup. Psychiatry Res., 1993, 49, 63-75.
86. Mallya, G. K.; White, K.; Waternaux, C.; Quay, S. Short and longterm treatment of obsessive-compulsive disorder with fluvoxamine. Ann. Clin. Psychiatry, 1992, 4, 77-80.
87. Hollander, E.; Koran, L. M.; Goodman, W. K.; Greist, J. H.; Ninan, P. T.; Yang, H.; Li, D.; Barbato, L. M. A double-blind, placebocontrolled study of the efficacy and safety of controlled-release fluvoxamine in patients with obsessive-compulsive disorder. J. Clin. Psychiatry, 2003, 64, 640-647.
88. Ordacgi, L.; Mendlowicz, M. V.; Fontenelle, L. F. Management of obsessive-compulsive disorder with fluvoxamine extended release. Neuropsychiatr. Dis. Treat., 2009, 5, 301-308.
89. Owen, R. T. Controlled-release fluvoxamine in obsessivecompulsive disorder and social phobia. Drugs Today (Barc). 2008, 44, 887-893.
90. Chouinard, G.; Goodman, W.; Greist, J.; Jenike, M.; Rasmussen, S.; White, K.; Hackett, E.; Gaffney, M.; Bick, P. A. Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. Psychopharmacol. Bull., 1990, 26, 279-284.
91. Kronig, M. H.; Apter, J.; Asnis, G.; Bystritsky, A.; Bystritsky, A.; Curtis, G.; Ferguson, J.; Landbloom, R.; Munjack, D.; Riesenberg, R.; Robinson, D.; Roy-Byrne, P.; Phillips, K.; Du Pont, I. J. Placebo-controlled, multi-centre study of sertraline study for obsessive-compulsive disorder. J. Clin. Psychopharmacol., 1999, 19, 172-176.
92. Jenike, M. A.; Baer, L.; Summergrad, P.; Minichiello, W. E.; Holland, A.; Seymour, R. Sertraline in obsessive-compulsive disorder: a double-blind comparison with placebo. Am. J. Psychiatry, 1990, 147, 923-928.
93. Rasmussen, S. A.; Baer, L.; Shera, D. Previous treatment and efficacy of sertraline for OCD: combined analysis of 4 multicenter trials. Annual meeting of the American Psychiatric Association, San Diego, CA, 1997; pp. 17-22.
94. Greist, J.; Chouinard, G.; DuBoff, E.; Halaris, A.; Kim, S. W.; Koran, L.; Liebowitz, M.; Lydiard, R. B.; Rasmussen, S.; White, K.; et al. Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1995, 52, 289-295.
95. Bogetto, F.; Albert, U.; Maina, G. Sertraline treatment of obsessive-compulsive disorder: efficacy and tolerability of a rapid titration regimen. Eur. Neuropsychopharmacol., 2002, 12, 181-186.
96. Koran, L. M.; Hackett, E.; Rubin, A.; Wolkow, R.; Robinson, D. Efficacy of sertraline in the long-term treatment of obsessivecompulsive disorder. Am. J. Psychiatry, 2002, 159, 88-95.
97. Bergeron, R.; Ravindran, A. V.; Chaput, Y.; Goldner, E.; Swinson, R.; Van Ameringen, M. A.; Austin, C.; Hadrava, V. Sertraline and fluoxetine treatment of obsessive-compulsive disorder: results of a double-blind, 6-months study. J. Clin. Psychopharmacol., 2002, 22, 148-154.
98. Weadon, D.; Bushnell, W. D.; Steiner, M. A fixed dose comparison of 20, 40,or 60mg of paroxetine to placebo in the treatment of obsessive-compulsive disorder. The American College of Neuropsychopharmacology, Annual Meeting, Puerto Rico, 1993.
99. Zohar, J.; Judge, R. Paroxetine versus clomipramine in the treatment of obsessive-compulsive disorder. Br. J. Psychiatry, 1996, 169, 468-474.
100. White, K.; Keck, P. E. Jr.; Lipinski, J. Serotonin-uptake inhibitors in obsessive-compulsive disorder: a case report. Compr. Psychiatry, 1986, 27, 211-214.
101. Marazziti, D.; Dell'Osso, L.; Gemignani, A.; Ciapparelli, A.; Presta, S.; Nasso, E. D.; Pfanner, C.; Cassano, G. B. Citalopram in refractory obsessive-compulsive disorder: an open study. Int. Clin. Psychopharmacol., 2001, 16, 215-219.
102. Pallanti, S.; Quercioli, L.; Koran, L. M. Citalopram intravenous infusion in resistant obsessive-compulsive disorder: an open trial. J. Clin. Psychiatry, 2002, 63, 796-801.
103. Stein, D. J.; Andersen, E. W.; Tonnoir, B.; Fineberg, N. Escitalopram in obsessive-compulsive disorder: a randomized, placebocontrolled, paroxetine-referenced, fixed-dose, 24-week study. Curr. Med. Res. Opin., 2007, 23, 701-711.
104. Fineberg, N. A.; Tonnoir, B.; Lemming, O.; Stein, D. J. Escitalopram prevents relapse of obsessive-compulsive disorder. Eur. Neuropsychopharmacol., 2007, 17, 430-439.
105. Ananth, J.; Burgoyne, K.; Smith, M.; Swartz, R. Venlafaxine for treatment of obsessive-compulsive disorder. Am. J. Psychiatry, 1995, 152, 1832.
106. Grossman, R.; Hollander, E. Treatment of obsessive-compulsive disorder with venlafaxine. Am. J. Psychiatry, 1996, 153, 576-577.
107. Rauch, S. L.; O'Sullivan, R. L.; Jenike, M. A. Open treatment of obsessive-compulsive disorder with venlafaxine: a series of ten cases. J. Clin. Psychopharmacol., 1996, 16, 81-84.
108. Yaryura-Tobias, J. A.; Neziroglu, F. A. Venlafaxine in obsessivecompulsive disorder. Arch. Gen. Psychiatry, 1996, 53, 653-654.
109. Albert, U.; Aguglia, E.; Maina, G.; Bogetto, F. Venlafaxine versus clomipramine in the treatment of obsessive-compulsive disorder: a preliminary single-blind, 12-week, controlled study. J. Clin. Psychiatry, 2002, 63, 1004-1009.
110. Hollander, E.; Friedberg, J.; Wasserman, S.; Allen, A.; Birnbaum, M.; Koran, L. M. Venlafaxine in treatment-resistant obsessivecompulsive disorder. J. Clin. Psychiatry, 2003, 64, 546-550.
111. Denys, D.; van der Wee, N.; van Megen, H.; Westenberg, H. A double-blind comparison of venlafaxine and paroxetine in obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2003, 23, 568-575.
112. Denys, D.; Van Nieuwerburgh, F.; Deforce, D.; Westenberg, H. G. Prediction of response to paroxetine and venlafaxine by serotoninrelated genes in obsessive-compulsive disorder in a randomized, double-blind trial. J. Clin. Psychiatry, 2007, 68, 747-753.
113. Dell'Osso, B.; Mundo, E.; Marazziti, D.; Altamura, A. C. Switching from serotonin reuptake inhibitors to duloxetine in patients with resistant obsessive compulsive disorder: a case series. J. Psychopharmacol., 2008, 22, 210-213.
114. McDougle, C. J.; Goodman, W. K.; Lechman, J. F.; Price, L. H. The psychopharmacology of obsessive-compulsive disorder: implications for treatment and pathogenesis. Psychiatry Clin. North Am., 1993, 16, 749-766.
115. Marazziti, D.; Catena, M.; Pallanti, S. Pharmacological treatment of obsessive-compulsive disorder. Psychiatry Annals, 2006, 36, 454-462.
116. Marazziti, D.; Mungai, F.; Vivarelli, L.; Dell'Osso, B. Critical issues in the pharmacological treatment of obsessive-compulsive disorder. Clin. Neuropsychiatry, 2004, 1, 59-64.
117. World Federation of Societies of Biological Psychiatry (WFSBP). Guidelines for the pharmacological treatment of anxiety, obsessivecompulsive and post-traumatic stress disorders first revision. World J. Biol. Psychiatry, 2008, 9, 248-312.
118. Mattes, J. A pilot study of combined trazodone and tryptophan in obsessive-compulsive disorder. Int. Clin. Psychopharmacol., 1986, 1, 170-173.
119. McDougle, C. J. Update on pharmacologic management of OCD: agents and augmentation. J. Clin. Psychiatry, 1997, 58, 11-17.
120. Simeon, J. C.; Thatte, S.; Wiggins, D. Treatment of adolescent obsessive-compulsive disorder with a clomipramine-fluoxetine combination. Psychopharmacol. Bull., 1990, 26, 285-290.
121. Browne, M.; Horn, E.; Jones, T. T. The benefits of Clomipraminefluoxetine combination in obsessive-compulsive disorder. Can. J. Psychiatry, 1993, 38, 242-243.
122. Marazziti, D.; Golia, F.; Consoli, G.; Presta, S.; Pfanner, C.; Carlini, M.; Mungai, F.; Catena Dell'osso, M. Effectiveness of longterm augmentation with citalopram to clomipramine in treatmentresistant OCD patients. CNS Spectr., 2008, 13, 971-976.
123. Dannon, P. N.; Sasson, Y.; Hirschmann, S.; Iancu, I.; Grunhaus, L. J.; Zohar, J. Pindolol augmentation in treatment-resistant obsessive compulsive disorder: a double-blind placebo controlled trial. Eur. Neuropsychopharmacol., 2000, 10, 165-169.
124. Mundo, E.; Guglielmo, E.; Bellodi, L. Effect of adjuvant pindolol on the antiobsessional response to fluvoxamine: a double-blind, placebo-controlled study. Int. Clin. Psychopharmacol. 1998, 13, 219-224.
125. McDougle, C. J.; Goodman, W. K.; Leckman, J. F.; Lee, N. C.; Heninger, G. R.; Price, L. H. Haloperidol addition in fluvoxaminerefractory obsessive-compulsive disorder: a double-blind, placebocontrolled study in patients with and without tics. Arch. Gen. Psychiatry, 1994, 51, 302-308.
126. Saxena, S.; Wang, D.; Bystritsky, A.; Baxter, L. R. Jr. Risperidone augmentation of SRI treatment for refractory obsessive-compulsive disorder. J. Clin. Psychiatry, 1996, 57, 303-306.
127. McDougle, C. J.; Epperson, C. N.; Pelton, G. H.; Wasylink, S.; Price, L. H. A double-blind, placebo-controlled study of risperidone addition in serotonin reuptake inhibitor refractory obsessivecompulsive disorder. Arch. Gen. Psychiatry, 2000, 57, 794-801.
128. Hollander, E.; Rossi, N. B.; Sood, E.; Pallanti, S. Risperidone augmentation in treatment-resistant obsessive-compulsive disorder: a double-blind, placebo-controlled study. Int. J. Neuropsychopharmacol., 2003, 6, 397-401.
129. D'Amico, G.; Cedro, C.; Muscatello, M. R.; Pandolfo, G.; Di Rosa, A. E.; Zoccali, R.; La Torre, D.; D'Arrigo, C.; Spina, E. Olanzapine augmentation of paroxetine-refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2003, 27, 619-623.
130. Bogetto, F.; Bellino, S.; Vaschetto, P.; Ziero, S. Olanzapine augmentation of fluvoxamine-refractory obsessive-compulsive disorder (OCD): a 12-week open trial. Psychiatry Res., 2000, 96, 91-98.
131. Shapira, N. A.; Ward, H. E.; Mandoki, M.; Murphy, T. K.; Yang, M. C.; Blier, P.; Goodman, W. K. A double-blind, placebocontrolled trial of oloanzapine addition in fluoxetine-refractory obsessive-compulsive disorder. Biol. Psychiatry, 2004, 55, 553-555.
132. Marazziti, D.; Pfanner, C.; Dell'Osso, B.; Ciapparelli, A.; Presta, S.; Corretti, G.; Di Nasso, E.; Mungai, F.; Dell'Osso, L. Augmentation strategy with olanzapine in resistant obsessive-compulsive disorder: an Italian long-term open-label study. J. Psychopharmacol., 2005, 19, 392-394.
133. Maina, G.; Pessina, E.; Albert, U.; Bogetto, F. 8-week, singleblind, randomized trial comparing risperidone versus olanzapine augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder. Eur. Neuropsychopharmacol., 2008, 18, 364-372.
134. Atmacha, M.; Kuloglu, M.; Tezcan, E.; Gecici, O. Quetiapine augmentation in patients with treatment resistant obsessivecompulsive disorder: a single-blind, placebo-controlled study. Int. Clin. Psychopharmacol., 2002, 17, 115-119.
135. Denys, D.; De Geus, F.; Van Megen, H. J.; Westenberg, H. G. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors. J. Clin. Psychiatry, 2004, 65, 1040-1048.
136. Fineberg, N. A.; Sivakumaran, T.; Roberts, A.; Gale, T. Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int. Clin. Psychopharmacol., 2005, 20, 223-226.
137. Mohr, N.; Vythilingum, B.; Emsley, R. A.; Stein, D. J. Quetiapine augmentation of serotonin reuptake inhibitors in obsessivecompulsive disorder. Int. Clin. Psychopharmacol., 2002, 17, 37-40.
138. Sevincok, L.; Topuz, A. Lack of efficacy of low doses of quetiapine addition in refractory obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2003, 23, 448-450.
139. Pessina, E.; Albert, U.; Bogetto, F.; Maina, G. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 12-week open-label preliminary study. Int. Clin. Psychopharmacol., 2009, 24, 265-269.
140. Iglesias Garcia, C.; Santamarina Montila, S.; Alonso Villa, M. J. Ziprasidone as coadjuvant treatment in resistant obsessivecompulsive disorder treatment. Actas Esp. Psiquiatr., 2006, 34, 277-279.
141. Savas, H. A.; Yumru, M.; Ozen, M. E. Quetiapine and ziprasidone as adjuncts in treatment-resistant obsessive-compulsive disorder: a retrospective comparative study. Clin. Drug Investig., 2008, 28, 439-442.
142. Van Ameringen, M.; Mancini, C.; Patterson, B.; Bennett, M. Topiramate augmentation in treatment-resistant obsessive-compulsive disorder: a retrospective, open-label case series. Depress Anxiety, 2006, 23, 1-5.
143. Bloch, M. H.; Landeros-Weisenberger, A.; Kelmendi, B.; Coric, V.; Bracken, M. B.; Leckman, J. F. A systematic review: antipsychotic augmentation with treatment refractory obsessivecompulsive disorder. Mol. Psychiatry, 2006, 11, 622-632.
144. Skapinakis, P.; Papatheodorou, T.; Mavreas, V. Antipsychotic augmentation of serotonergic antidepressants in treatment-resistant obsessive-compulsive disorder: a meta-analysis of the randomized controlled trials. Eur. Neuropsychopharmacol., 2007, 17, 79-93.
145. Koran, L. M.; Aboujaoude, E.; Ward, H.; Shapira, N. A.; Sallee, F. R.; Gamel, N.; Elliott, M. Pulse-loaded intravenous clomipramine in treatment-resistant obsessive-compulsive disorder. J. Clin. Psychopharmacol., 2006, 26, 79-83.
146. Benjamin, J.; Levine, J.; Fux, M.; Aviv, A.; Levy, D.; Belmaker, R. H. Double-blind, placebo-controlled, crossover trial of inositol treatment for panic disorder. Am. J. Psychiatry, 1995, 152, 1084-1086.
147. Levine, J.; Barak, Y.; Gonzalves, M.; Szor, H.; Elizur, A.; Kofman, O.; Belmaker, R. H. Double-blind, controlled trial of inositol treatment of depression. Am. J. Psychiatry, 1995, 152, 792-794.
148. Fux, M.; Benjamin, J.; Belmaker, R. H. Inositol versus placebo augmentation of serotonin reuptake inhibitors in the treatment of obsessive-compulsive disorder: a double-blind cross-over study. Int. J. Neuropsychopharmacol., 1999, 2, 193-195.
149. Seedat, S.; Stein, D. J. Inositol augmentation of serotonin reuptake inhibitors in treatment-refractory obsessive-compulsive disorder: an open trial. Int. Clin. Psychopharmacol., 1999, 14, 353-356.
150. Carey, P. D.; Warwick, J.; Harvey, B. H.; Stein, D. J.; Seedat, S. Single photon emission computed tomography (SPECT) in obsessive-compulsive disorder before and after treatment with inositol. Metab. Brain Dis., 2004, 19, 125-134.
151. Bhattacharyya, S.; Chakraborty, K. Glutamatergic dysfunction-newer targets for anti-obsessional drugs. Recent Pat. CNS Drug Discov., 2007, 2, 47-55.
152. Walker, D. L.; Ressler, K. J.; Lu, K. T.; Davis, M. Facilitation of conditioned fear extinction by systemic administration or intraamygdala infusions of D-cycloserine as assessed with fearpotentiated startle in rats. J. Neurosci., 2002, 22, 2343-2351.
153. Hofmann, S. G.; Meuret, A. E.; Smits, J. A.; Simon, N. M.; Pollack, M. H.; Eisenmenger, K.; Shiekh, M.; Otto, M. W. Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch. Gen. Psychiatry, 2006, 63, 298-304.
154. Guastella, A. J.; Dadds, M. R.; Lovibond, P. F.; Mitchell, P.; Richardson, R. A randomized controlled trial of the effect of Dcycloserine on exposure therapy for spider fear. J. Psychiatr. Res., 2007, 41, 466-471.
155. Guastella, A. J.; Richardson, R.; Lovibond, P. F.; Rapee, R. M.; Gaston, J. E.; Mitchell, P.; Dadds, M. R. A randomized controlled trial of D-cycloserine enhancement of exposure therapy for social anxiety disorder. Biol. Psychiatry, 2008, 63, 544-549.
156. Kushner, M. G.; Kim, S. W.; Donahue, C.; Thuras, P.; Adson, D.; Kotlyar, M.; McCabe, J.; Peterson, J.; Foa, E. B. D-cycloserine augmented exposure therapy for obsessive-compulsive disorder. Biol. Psychiatry, 2007, 62, 835-838.
157. Wilhelm, S.; Buhlmann, U.; Tolin, D. F.; Meunier, S. A.; Pearlson, G. D.; Reese, H. E.; Cannistraro, P.; Jenike, M. A.; Rauch, S. L. Augmentation of behavior therapy with D-cycloserine for obsessive-compulsive disorder. Am. J. Psychiatry, 2008, 165, 335-341.
158. Boje, K. M.; Wong, G.; Skolnick, P. Desensitization of the NMDA receptor complex by glycinergic ligands in cerebellar granule cell cultures. Brain Res., 1993, 603, 207-214.
159. Coric, V.; Taskiran, S.; Pittenger, C.; Wasylink, S.; Mathalon, D. H.; Valentine, G.; Saksa, J.; Wu, Y. T.; Gueorguieva, R.; Sanacora, G.; Malison, R. T.; Krystal, J. H. Riluzole augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. Biol. Psychiatry, 2005, 58, 424-428.
160. Grant, P.; Lougee, L.; Hirschtritt, M.; Swedo, S. E. An open-label trial of riluzole, a glutamate antagonist, in children with treatmentresistant obsessive-compulsive disorder. J. Child Adolesc. Psychopharmacol., 2007, 17, 761-767.
161. Pasquini, M.; Biondi, M. Memantine augmentation for refractory obsessive-compulsive disorder. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2006, 30, 1173-1175.
162. Aboujaoude, E.; Barry, J. J.; Gamel, N. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial. J. Clin. Psychopharmacol., 2009, 29, 51-55.
163. Williams, T. I.; Salkovskis, P. M.; Forrester, L.; Turner, S.; White, H.; Allsopp, M. A. A randomised controlled trial of cognitive behavioral treatment for obsessive compulsive disorder in children and adolescents. Eur. Child. Adolesc. Psychiatry, 2010, 19, 449-456.
164. De Veaugh-Geiss, J.; Moroz, G.; Biederman, J.; Cantwell, D.; Fontaine, R.; Greist, J. H.; Reichler, R.; Katz, R.; Landau, P. Clomipramine hydrochloride in childhood and adolescent obsessivecompulsive disorder: a multicenter trial. J. Am. Acad. Child. Adolesc. Psychiatry, 1992, 31, 45-49.
165. Leonard, H. L.; Swedo, S. E.; Rapoport, J. L.; Koby, E. V.; Lenane, M. C.; Cheslow, D. L.; Hamburger, S. D. Treatment of obsessive compulsive disorder with clomipramine and desipramine in children and adolescents: a double-blind crossover comparison. Arch. Gen. Psychiatry, 1989, 46, 1088-1092.
166. Geller, D. A.; Biederman, J.; Stewart, S. E.; Mullin, B.; Martin, A.; Spencer, T.; Faraone, S. V. Which SSRI? A meta-analysis of pharmacotherapy trials in pediatric obsessive-compulsive disorder. Am. J. Psychiatry, 2003, 160, 1919-1928.
167. Leonard, H. L.; Swedo, S. E.; Lenane, M. C.; Rettew, D. C.; Cheslow, D. L.; Hamburger, S. D.; Rapoport, J. L. A double-blind desipramine substitution during long-term clomipramine treatment in children and adolescents with obsessive-compulsive disorder. Arch. Gen. Psychiatry, 1991, 48, 922-927.
168. Swedo, S. E.; Leonard, H. L.; Garvey, M.; Mittleman, B.; Allen, A. J.; Perlmutter, S.; Lougee, L.; Dow, S.; Zamkoff, J.; Dubbert, B. K. Pediatric autoimmune neuropsychiatric disorders associated with streptococcal infections: clinical description of the first 50 cases. Am. J. Psychiatry, 1998, 155, 264-271.
169. Grenier, S.; Préville, M.; Boyer, R.; O'Connor, K. Scientific Committee of the ESA Study. Prevalence and correlates of obsessivecompulsive disorder among older adults living in the community. J. Anxiety Disord., 2009, 23, 858-865.
170. Kirmizioglu, Y.; Do an, O.; Ku u, N.; Akyüz, G. Prevalence of anxiety disorders among elderly people. Int. J. Geriatr. Psychiatry, 2009, 24, 1026-1033.
171. Calamari, J. E.; Faber, S. D.; Hitsman, B. L.; Poppe, C. J. Treatment of obsessive compulsive disorder in the elderly: a review and case example. J. Behav. Ther. Exp. Psychiatry, 1994, 25, 95-104.
172. Agarwal, A.; Biswas, D.; Sadhu, R. Treatment for late-onset obsessive-compulsive disorder with parkinsonism. J. Neuropsychiatry Clin. Neurosci., 2008, 20, 331-336.
173. Jackson, C. W. Obsessive-compulsive disorder in elderly patients. Drugs Aging, 1995, 7, 438-448.
174. Hendriks, G. J.; van Rees, M. M.; Verbraak, M. J.; Keijsers, G. P.; Hoogduin, C. A. Treatment of obsessive-compulsive disorder in older patients case studies. Tijdschr. Psychiatr., 2008, 50, 617-621.
175. Ayers, C. R.; Saxena, S.; Golshan, S.; Wetherell, J. L. Age at onset and clinical features of late life compulsive hoarding. Int. J. Geriatr. Psychiatry, 2010, 25, 142-149.